Kantar Health Blog

  • Arnold DuBell
    Oncology Conference Insight: ASCO 2015 --- Immunotherapy has dominated the conversation in oncology for the past several years, and the excitement still hasn’t waned at all - in fact it continues to grow. New drugs have entered development in this space, new mechanisms of action have emerged, and new tumor types have entered the focus of our attention. We have previously seen various level of evidence to support the activity of checkpoint inhibitors in melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, breast cancer, gastric cancer, head and neck cancer, and Hodgkin’s lymphoma. At this year’s annual meeting of the American Society of Clinical Oncology, we observed first reports of the activity of several PD-1 and PD-L1 inhibitors in multiple new tumor indications, adding to the growing body of evidence that suggests immunotherapy is closely approaching panacea status.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- In several B-cell malignancies, physicians have a number of new options for their patients, allowing these patients the promise of being treated for several lines of therapy. For chronic lymphocytic leukemia (CLL) and indolent lymphoma patients, physicians now have the option to use kinase inhibitors such as Imbruvica® (ibrutinib, Pharmacyclics/Janssen) or Zydelig® (idelalisib, Gilead). For multiple myeloma patients, physicians now have the option to utilize Kyprolis® (carfilzomib, Amgen/Onyx) or Pomalyst® (pomalidomide, Celgene).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- Rituxan® (rituximab, Roche/Genentech) forms the backbone of virtually every aspect of therapeutic management for B-cell non-Hodgkin’s Lymphoma (NHL); however, while clinically effective, approximately 20% of patients with indolent NHL (iNHL) are considered Rituxan-refractory. This poses an unmet need for patients, leaving them historically with only chemotherapy as a treatment option.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- The treatment armamentarium available for patients with advanced melanoma has become quite well stocked as recent progress in the development of novel therapeutic agents has been tremendous. Immune checkpoint inhibition and targeted inhibition of BRAF and MEK are two therapeutic approaches that have significantly improved survival for patients with advanced melanoma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- Two important drugs obtained FDA approval last year for use in relapsed/refractory chronic lymphocytic leukemia (CLL): Imbruvica® (ibrutinib, Pharmacyclics/Janssen) as a single agent in February 2014 and Zydelig® (idelalisib, Gilead) in combination with Rituxan® (rituximab, Genentech/Roche) in July 2014. Still, better treatment options with greater therapeutic outcomes are strongly needed in CLL treatment in order to prolong survival in these patients.
    Continue Reading > | Go comment! | Share